By Nascent Biotech Posted November 4, 2019 In hab1803482019-11-042019-11-04http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 hab180348 Recent PostsNascent Biotech to Begin Phase II Clinical Trials for Brain CancerBenzinga: Why NBIO is a Biotech Bargain Basement Deal with Underappreciated PotentialJournal of Clinical Oncology: Phase 1 study of pritumumab in brain cancer.Nascent Biotech Regains Worldwide Rights for Pritumumab
